0001209191-19-054164.txt : 20191025
0001209191-19-054164.hdr.sgml : 20191025
20191025171255
ACCESSION NUMBER: 0001209191-19-054164
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190920
FILED AS OF DATE: 20191025
DATE AS OF CHANGE: 20191025
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Galante Joseph C
CENTRAL INDEX KEY: 0001632384
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33637
FILM NUMBER: 191170689
MAIL ADDRESS:
STREET 1: 111 TENTH AVENUE
STREET 2: SUITE 200
CITY: NASHVILLE
STATE: TN
ZIP: 37203
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CUMBERLAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001087294
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
BUSINESS ADDRESS:
STREET 1: 2525 WEST END AVENUE
STREET 2: SUITE 950
CITY: NASHVILLE,
STATE: TN
ZIP: 37203
BUSINESS PHONE: 615-255-0068
MAIL ADDRESS:
STREET 1: 2525 WEST END AVENUE
STREET 2: SUITE 950
CITY: NASHVILLE
STATE: TN
ZIP: 37203
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-09-20
0
0001087294
CUMBERLAND PHARMACEUTICALS INC
CPIX
0001632384
Galante Joseph C
2525 WEST END AVENUE
SUITE 950
NASHVILLE
TN
37203
1
0
0
0
Common Stock
2019-09-20
4
P
0
60
5.33
A
15578
D
Common Stock
2019-09-23
4
P
0
60
5.35
A
15638
D
Common Stock
2019-09-24
4
P
0
60
5.39
A
15698
D
Common Stock
2019-09-25
4
P
0
60
5.38
A
15758
D
Common Stock
2019-09-26
4
P
0
60
5.76
A
15818
D
Common Stock
2019-09-27
4
P
0
60
5.76
A
15878
D
Common Stock
2019-09-30
4
P
0
60
5.89
A
15938
D
Common Stock
2019-10-01
4
P
0
60
5.89
A
15998
D
Common Stock
2019-10-02
4
P
0
60
5.77
A
16058
D
Common Stock
2019-10-04
4
P
0
60
5.76
A
16118
D
Common Stock
2019-10-07
4
P
0
60
5.74
A
16178
D
Common Stock
2019-10-08
4
P
0
60
5.81
A
16238
D
Common Stock
2019-10-09
4
P
0
60
5.78
A
16298
D
Common Stock
2019-10-10
4
P
0
60
5.86
A
16358
D
Common Stock
2019-10-11
4
P
0
60
5.71
A
16418
D
Common Stock
2019-10-14
4
P
0
60
5.67
A
16478
D
Common Stock
2019-10-15
4
P
0
60
5.63
A
16538
D
Common Stock
2019-10-16
4
P
0
60
5.56
A
16598
D
Common Stock
2019-10-17
4
P
0
60
5.52
A
16658
D
Common Stock
2019-10-18
4
P
0
34
5.45
A
16692
D
The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.
Joseph C. Galante by /s/ Michael Bonner as
attorney-in-fact
2019-10-25